P2Y12 inhibitor

Phase 3Small molecule

UUnknown Sponsor

P2Y12 inhibitor is one of 84 small molecule programs targeting Acute Coronary Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Coronary SyndromeActive, not recruiting

Atrial FibrillationRecruiting

Acute Coronary SyndromePreclinical

Active, not recruiting

Atrial FibrillationPhase 3

Recruiting

Competition

Competitive Landscape

137 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

P2Y12 inhibitor

UUnknown Sponsor

Phase 3

1 2

Calquence

AstraZeneca

Preclinical

1 3

Rituxan

Brukinsa

1 5

Imbruvica

PPharmacyclics LLC.

Preclinical

1 6

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 7

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 8

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

1 10

SGLT2 Inhibitor

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Atrial Fibrillation

NCT05955365

Q1 2028

Phase 3Recruiting

Pneumonia

NCT02735707

Clinical

Trials by Indication[1]

High Bleeding Risk2 trials

Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen

Completed·EECRI bv·N/A·NCT03023020·4,579 enrolled

Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT

Unknown status·UUnknown Sponsor·Phase 4·NCT03112707·1,023 enrolled

Atrial Fibrillation1 trial

Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation

Recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT05955365·3,010 enrolled

Pneumonia1 trial

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting·UUMC Utrecht·Phase 3·NCT02735707·20,000 enrolled

Antiplatelet Therapy1 trial

Colonoscopy and Antiplatelet Therapy Trial

Not yet recruiting·OOchsner Health System·Phase 4·NCT06613191·100 enrolled

Acute Coronary Syndrome1 trial

Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE)

Unknown status·SSamsung Medical Center·N/A·NCT01701453·2,712 enrolled

1 more indication

Unspecified1 trial

Study of AggreGuide A-100 (ADP) Assay

Completed·AAggredyne, Inc.·N/A·NCT03111420·280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for P2Y12 inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — P2Y12 inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for P2Y12 inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Unknown Sponsor company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUnknown Sponsor

P2Y12 inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Trials by Indication[1]

High Bleeding Risk2 trials

Atrial Fibrillation1 trial

Pneumonia1 trial

Antiplatelet Therapy1 trial

Acute Coronary Syndrome1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News